Phase I study to evaluate the safety and tolerability of single and multiple doses of intranasal pentosan polysulfate (Rhinosul 'Trademark') in healthy subjects
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Pentosan polysulfate (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Paradigm Pharmaceuticals
- 09 Sep 2016 Status changed from recruiting to completed.
- 29 Jun 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 New trial record